.png){kind=icon}
返回
Myasthenia gravis
.png){kind=icon}
PRE
AI
DOI：10.1038/s41572-019-0079-y.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane. Localized or general muscle weakness is the predominant symptom and is induced by the antibodies. Patients are grouped according to the presence of antibodies, symptoms, age at onset and thymus pathology. Diagnosis is straightforward in most patients with typical symptoms and a positive antibody test, although a detailed clinical and neurophysiological examination is important in antibody-negative patients. MG therapy should be ambitious and aim for clinical remission or only mild symptoms with near-normal function and quality of life. Treatment should be based on MG subgroup and includes symptomatic treatment using acetylcholinesterase inhibitors, thynnectonny and innnnunotherapy. Intravenous immunoglobulin and plasma exchange are fast-acting treatments used for disease exacerbations, and intensive care is necessary during exacerbations with respiratory failure. Comorbidity is frequent, particularly in elderly patients. Active physical training should be encouraged.
Keyword:
QUALITY-OF-LIFE
NICOTINIC ACETYLCHOLINE-RECEPTOR
LATE-ONSET MYASTHENIA
CLINICAL CHARACTERISTICS
MYCOPHENOLATE-MOFETIL
PROTEIN 4
INTRAVENOUS IMMUNOGLOBULIN
IGG4 AUTOANTIBODIES
RANDOMIZED-TRIAL
STRUCTURAL BASIS
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
N
IF:
60.6
论文数:
650
被引数:
3.8W
机构
引用论文
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.png)
NEUROLOGY
NEUROLOGYIF8.5
PREAI
分享收藏
Defective lens fiber differentiation and pancreatic tumorigenesis caused by ectopic expression of the cellular retinoic acid-binding protein IDevelopment
DevelopmentIF0
PREAI
分享收藏
查看更多内容